Truist Financial Reaffirms “Buy” Rating for Vericel (NASDAQ:VCEL)

Vericel (NASDAQ:VCEL)‘s stock had its “buy” rating reiterated by equities research analysts at Truist Financial in a report released on Monday,Benzinga reports. They presently have a $50.00 price objective on the biotechnology company’s stock, up from their prior price objective of $41.00. Truist Financial’s price target points to a potential upside of 29.98% from the company’s previous close.

Several other equities research analysts also recently commented on VCEL. BTIG Research downgraded Vericel from a “buy” rating to a “neutral” rating in a report on Wednesday, September 17th. Canaccord Genuity Group lowered their price objective on shares of Vericel from $61.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, August 1st. Wall Street Zen raised shares of Vericel from a “hold” rating to a “buy” rating in a research report on Saturday. Zacks Research upgraded shares of Vericel from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. Finally, Weiss Ratings raised shares of Vericel from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $60.20.

Vericel Stock Down 1.2%

Shares of Vericel stock traded down $0.47 during trading hours on Monday, hitting $38.47. The company’s stock had a trading volume of 145,773 shares, compared to its average volume of 566,405. The business has a fifty day moving average of $33.78 and a 200 day moving average of $37.70. Vericel has a 1-year low of $29.24 and a 1-year high of $63.00. The company has a market capitalization of $1.94 billion, a PE ratio of 320.59 and a beta of 1.41.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Thursday, November 6th. The biotechnology company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.12. Vericel had a net margin of 2.85% and a return on equity of 2.47%. The firm had revenue of $67.50 million during the quarter, compared to analysts’ expectations of $64.57 million. During the same period in the prior year, the company earned ($0.02) EPS. The firm’s revenue was up 16.6% on a year-over-year basis. Vericel has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Vericel will post 0.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vericel

A number of institutional investors have recently modified their holdings of the business. Ameritas Advisory Services LLC acquired a new stake in shares of Vericel during the 2nd quarter worth approximately $30,000. Abich Financial Wealth Management LLC bought a new position in shares of Vericel in the third quarter valued at approximately $31,000. CWM LLC increased its position in shares of Vericel by 101.3% during the 2nd quarter. CWM LLC now owns 1,379 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 694 shares during the period. AlphaQuest LLC bought a new stake in Vericel in the second quarter worth about $60,000. Finally, Osaic Holdings Inc. raised its holdings in shares of Vericel by 13.7% in the 2nd quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 353 shares in the last quarter.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.